Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis

• Published in: Clinical and molecular hepatology 2016, 22(1), , pp.160-167
• Main Authors: Lee, Jung Min, Jang, Byoung Kuk, Lee, Yoo Jin, Choi, Wang Yong, Choi, Sei Myong, Chung, Woo Jin, Hwang, Jae Seok, Kang, Koo Jeong, Kim, Young Hwan, Chauhan, Anil Kumar, Park, Soo Young, Tak, Won Young, Kweon, Young Oh, Kim, Byung Seok, Lee, Chang Hyeong
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Cancer therapies; Carcinoma, Hepatocellular - complications; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - therapy; Chemoembolization; Chemoembolization, Therapeutic; Combined Modality Therapy; Etiology; Female; Follow-Up Studies; Hepatic resection; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Humans; Inhibitor drugs; Liver cancer; Liver cirrhosis; Liver diseases; Liver Neoplasms - complications; Liver Neoplasms - drug therapy; Liver Neoplasms - therapy; Male; Medical prognosis; Middle Aged; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Original; Patients; Phenylurea Compounds - therapeutic use; Portal Vein; Portal vein tumor thrombosis; Proportional Hazards Models; Radiation; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Targeted cancer therapy; Thrombosis; Transarterial chemoembolization; Treatment Outcome; Veins & arteries; Venous Thrombosis - complications; 내과학
• ISSN: 2287-2728; 2287-285X
• DOI: 10.3350/cmh.2016.22.1.160

Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial. We compared the outcomes of hepatic resection (HR), transarterial chemoembolization (TACE), and sorafenib therapy as treatments for HCC with PVTT. Patients diagnosed as HCC with PVTT between January 2000 and December 2011 who received treatment with sorafenib, HR, or TACE were included. Patients with main PVTT, superior mesenteric vein tumor thrombosis, or Child-Turcotte-Pugh (CTP) class C were excluded. The records of 172 patients were analyzed retrospectively. HR, TACE, and sorafenib treatment were performed is 40, 80, and 52 patients respectively. PVTT was classified as either involving the segmental branch (type I) or extending to involve the right or left portal vein (type II). The median survival time was significantly longer in the HR group (19.9 months) than in the TACE and sorafenib groups (6.6 and 6.2 months, respectively; both p